A model for harmonizing flow cytometry in clinical trials.
Complexities in sample handling, instrument setup and data analysis are barriers to the effective use of flow cytometry to monitor immunological parameters in clinical trials. The novel use of a central laboratory may help mitigate these issues.
Maecker
Holden T
HT
Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, California, USA. maecker@stanford.edu
McCoy
J Philip
JP
Amos
Michael
M
Elliott
John
J
Gaigalas
Adolfas
A
Wang
Lili
L
Aranda
Richard
R
Banchereau
Jacques
J
Boshoff
Chris
C
Braun
Jonathan
J
Korin
Yael
Y
Reed
Elaine
E
Cho
Judy
J
Hafler
David
D
Davis
Mark
M
Fathman
C Garrison
CG
Robinson
William
W
Denny
Thomas
T
Weinhold
Kent
K
Desai
Bela
B
Diamond
Betty
B
Gregersen
Peter
P
Di Meglio
Paola
P
DiMeglio
Paola
P
Nestle
Frank O
FO
Nestle
Frank
F
Peakman
Mark
M
Villanova
Federica
F
Villnova
Federica
F
Ferbas
John
J
Field
Elizabeth
E
Kantor
Aaron
A
Kawabata
Thomas
T
Komocsar
Wendy
W
Lotze
Michael
M
Nepom
Jerry
J
Ochs
Hans
H
O'Lone
Raegan
R
Phippard
Deborah
D
Plevy
Scott
S
Rich
Stephen
S
Roederer
Mario
M
Rotrosen
Dan
D
Yeh
Jung-Hua
JH
D002986:Clinical Trials as Topic; D005434:Flow Cytometry / Q000379:methods* / Q000592:standards*; D006801:Humans; D013048:Specimen Handling